首页> 外文期刊>Acta Neurochirurgica >S100B, intraoperative neuromonitoring findings and their relation to clinical outcome in surgically treated intradural spinal lesions
【24h】

S100B, intraoperative neuromonitoring findings and their relation to clinical outcome in surgically treated intradural spinal lesions

机译:S100B,术中神经监测的发现及其在外科治疗的硬脊膜内病变中与临床结局的关系

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Neurophysiological monitoring (IOM) consisting of somatosensory (SEPs), muscle (MEPs) and spinal motor evoked (D-wave; spinal MEPs) potentials is used to indicate injury related to surgical treatment of intradural and intramedullary lesions. Combining spinal and muscle MEPs reliably predicts long-term motor deficit. If spinal MEPs recording is not possible, additional markers - e.g. S100B, a serum marker for glial injury - may be a helpful adjunct. Thus, serial serum S100B measurements were related to both the intraoperative IOM recordings and the long-term neurological outcome in patients surgically treated for cervical and thoracic intradural lesions. Methods: In 33 patients (9 men, 24 women, 54±17 years) during intramedullary (8) or intradural (25) cervical or thoracic spinal surgeries significant intraoperative SEP-amplitude decrement >50 % or MEP loss and serial S100B serum concentration (perioperative days 0, 1-3, 5) were related to outcome (>1 year after discharge, grouped into improved and unchanged/altered neurological symptoms). Results: Differences in S100B levels between patients with improved and unchanged/altered neurological outcome were significantly on postoperative days 2 (0.085±0.08 μg/l vs 0.206±0.07 μg/l, p=0.005) and 3 (0.076±0.03 μg/l vs 0.12±0.05 μg/l, p=0.007). All patients with permanent altered neurological symptoms developed S100B levels >0.08 μg/l (0.09-0.35 μg/l). Eighty-one percent of patients with improved neurological symptoms presented with S100B levels ≤0.08 μg/l (0.02-0.08 μg/l). Nine out of ten patients (90 %) without changes in EP and S100B had an improved long-term outcome, whereas 9/13 patients (69 %) with changes in EP and S100B had altered neurological symptoms in long-term outcome. Conclusion: Intraoperative stable EPs and S100B≤0.08 μg/l may be used as a marker to predict long-term neurological improvement, whereas EP-changes and elevated S100B levels on the 3rd postoperative day may be useful as a marker to predict long-term neurological alteration. In summary, the combined use of S100B and EPs might be helpful in the prediction of the severity of adverse spinal cord affection following surgery and guidance of patients.
机译:背景:由体感(SEPs),肌肉(MEPs)和脊柱运动诱发(D波;脊柱MEPs)电位组成的神经生理监测(IOM)用于指示与硬膜内和髓内病变的外科手术治疗相关的损伤。结合脊髓和肌肉MEP可以可靠地预测长期运动功能障碍。如果无法记录脊柱MEP,请使用其他标记-例如S100B是神经胶质损伤的血清标志物-可能是有用的辅助药物。因此,在接受手术治疗的颈和胸硬膜内病变的患者中,血清S100B的连续测量与术中IOM记录和长期神经系统结局有关。方法:在33例(9名男性,24名女性,54±17岁)的髓内(8)或硬膜内(25)颈或胸椎外科手术中,术中SEP幅度减低> 50%或MEP丢失和连续S100B血清浓度(围手术期第0、1-3、5天与结局有关(出院后> 1年,分为改善和未改变/改变的神经系统症状)。结果:术后2天(0.085±0.08μg/ l vs 0.206±0.07μg/ l,p = 0.005)和3天(0.076±0.03μg/ l),神经功能改善和改变/改变的患者之间的S100B水平差异显着vs.0.12±0.05μg/ l,p = 0.007)。所有神经症状永久改变的患者的S100B水平均> 0.08μg/ l(0.09-0.35μg/ l)。改善神经系统症状的患者中有81%的患者S100B水平≤0.08μg/ l(0.02-0.08μg/ l)。十名患者中有九名(90%)的EP和S100B不变,其长期预后有所改善,而9/13例患者(69%)的EP和S100B有所改变,其长期预后的神经系统症状有所改变。结论:术中稳定的EPs和S100B≤0.08μg/ l可用作预测长期神经功能改善的标志物,而术后第三天的EP变化和S100B水平升高则可作为长期预测的标志物神经系统改变。总之,S100B和EP的联合使用可能有助于预测手术和患者指导后脊髓不良影响的严重程度。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号